More on RHHBY
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $51.45 |
|
|||
| Open | $51.59 | ||||
| 52 Wk High | $35.13 | ||||
| 52 Wk Low | $28.10 | ||||
| Day High | $51.87 | ||||
| Day Low | $51.34 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,653,533 | ||||
- FDA grants priority review to Genentech's Gazyva for kidney disease
- FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy
- Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC
- HSBC Downgrades Roche Holding (ROG:SW) (RHHBY) to Hold
- Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
- FDA grants priority review to Genentech's Enspryng for thyroid eye disease
- FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
- FDA accepts Genentech's application for Lunsumio and Polivy combo
- FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
- FDA grants priority review for Genentech's Tecentriq in stage III colon cancer
Entities mentioned with RHHBY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Industrial Production | View Related Stories »
- Show More...
